8月7日，伊克力西斯盘中下跌5.7%，报53.48美元/股，成交额1.02亿美元。
消息面上，公司于8月5日盘后公布最新季度财报，实际每股收益为0.82美元，虽超出市场一致预期的0.79美元，但本季度营收预期增速已从上一季度的21.51%放缓至10.71%，盈利增长动能边际减弱。市场此前对公司核心产品卡博替尼放量及管线推进（包括Zanzalintinib的III期Stellar-303试验及与默克合作的Stellar-316试验）抱有较高预期，财报公布后资金选择获利了结。
伊克力西斯是一家专注于癌症小分子治疗的生物科技公司，旗舰产品卡博替尼已获批多项适应症，主要临床候选药物赞扎替尼正在接受FDA审查。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.